Suppr超能文献

[吲达帕胺——用于合并高血糖和/或血脂异常的高血压患者的替代利尿剂]

[Indapamide--a substitute diuretic for hypertensives with hyperglycemia and/or dyslipidemia].

作者信息

Sharabi Y, Grossman E, Nussinovitch N, Katz A, Rachima-Moaz C, Rosenthal T

机构信息

Medical Dept. D, Chaim Sheba Medical Center, Tel Hashomer.

出版信息

Harefuah. 1996 Oct;131(7-8):233-6, 295.

PMID:8940516
Abstract

Diuretics are among the first drugs offered to the hypertensive patient. However, they can induce metabolic changes resulting in cardiovascular insult. Especially noteworthy are increased levels of glucose and lipids. Indapamide is a diuretic and vasodilator that does not raise blood glucose or lipid levels. We therefore investigated its use as a substitute diuretic in patients whose treatment had resulted in hyperglycemia and/or hyperlipidemia. In 24 hypertensives, Indapamide, 2.5 mg daily, replaced the diuretic therapy they were receiving. Blood pressure, blood glucose, hemoglobin A1C and lipid profile were measured before and every month during the 6 months of Indapamide treatment. Replacement of diuretics with Indapamide significantly reduced blood glucose from 148 +/- 53 mg/dl to 127 +/- 37, p = 0.05 HbA1C from 8.42 +/- 0.4 mg/dl to 7.7 +/- 2.0, p = 0.05; total cholesterol from 253 +/- 45 mg/dl to 228 +/- 43, p < 0.05; and triglycerides from 224 +/- 145 mg/dl to 176 +/- 91, p < 0.05. Blood pressure was better controlled with Indapamide than with previous medications. It was reduced from an average of 155 +/- 1 systolic and 89 +/- 8 diastolic (mm Hg), to 142 +/- 13 and 83 +/- 7, respectively, p < 0.05. We conclude that Indapamide is safe and effective in lowering blood pressure and contributes to better control of blood glucose and lipid levels in diabetic and dyslipidemic patients, compared to standard diuretics.

摘要

利尿剂是最早用于高血压患者的药物之一。然而,它们可引起代谢变化,导致心血管损害。尤其值得注意的是血糖和血脂水平升高。吲达帕胺是一种利尿剂和血管扩张剂,不会升高血糖或血脂水平。因此,我们研究了它在治疗导致高血糖和/或高血脂的患者中作为替代利尿剂的用途。在24名高血压患者中,每日服用2.5毫克吲达帕胺,取代他们正在接受的利尿剂治疗。在吲达帕胺治疗的6个月期间,每月测量血压、血糖、糖化血红蛋白A1C和血脂谱。用吲达帕胺替代利尿剂后,血糖从148±53毫克/分升降至127±37,p = 0.05;糖化血红蛋白A1C从8.42±0.4毫克/分升降至7.7±2.0,p = 0.05;总胆固醇从253±45毫克/分升降至228±43,p < 0.05;甘油三酯从224±145毫克/分升降至176±91,p < 0.05。与之前的药物相比,吲达帕胺对血压的控制更好。收缩压从平均155±1毫米汞柱和舒张压89±8毫米汞柱分别降至142±13和83±7,p < 0.05。我们得出结论,与标准利尿剂相比,吲达帕胺在降低血压方面安全有效,有助于更好地控制糖尿病和血脂异常患者的血糖和血脂水平。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验